FGFR3 and TP53 mutations describe two recognizable molecular pathways in UC, with FGFR3 mutations prevailing in low-grade, non-invasive tumours and TP53 mutations dominating in high-grade, invasive tumours. Here, FGFR3 is linked to neoplasm.